MétaCan
Menu
Back to cohort

Abstract C116: Novel ATR inhibitors with CNS penetrance developed by artificial intelligence

2025· article· en· W4415444620 on OpenAlexaff
Sarah Truong, Beibei Zhai, Louise Ramos, Mona Marzban, Fariba Ghaidi, Marshall Drew-Brook, Mehran Khodabandeh, Sara Ibrahim Omar, Jason Rolfe, Seyed Ali Saberali, Xiaoqi Chen, Dennis Brown, John Langlands, Jeffrey Bacha, Mads Daugaard

Bibliographic record

VenueMolecular Cancer Therapeutics · 2025
Typearticle
Languageen
FieldImmunology and Microbiology
Topicinterferon and immune responses
Canadian institutionsOvarian Cancer Canada
Fundersnot available
KeywordsDrug discoveryPenetranceKinaseCancerSynthetic biologyDNA damageDrugDNA repair

Abstract

fetched live from OpenAlex

Abstract DNA damage repair (DDR) enzymes, including Ataxia telangiectasia and Rad3-related protein serine/threonine kinase (ATR), are crucial for maintaining genomic stability in cells. Inhibition of DDR enzymes has proven to be a compelling therapeutic option for numerous cancer indications that can lead to cell death through replication stress or mitotic catastrophe. ATR inhibitors have shown promising effects on solid tumors, both as monotherapies and in combination with chemotherapy, radiotherapy, or immunotherapy. However, they lack the ability to effectively penetrate through the blood-brain barrier (BBB) into the central nervous system (CNS), making them suboptimal for treatment of brain tumors and metastases. Using a generative artificial intelligence approach called the Enki™ platform for drug discovery, we are developing a novel, potent, CNS-penetrating, and selective ATR inhibitor. The Enki™ platform generates candidate compounds using a generative AI and deep learning approach to search and optimize compound properties in a broad chemical space, including potency, target specificity, physicochemical properties, and ADMET characteristics. This platform was used to create a shortlist of de novo compounds with properties to selectively target ATR and penetrate into the CNS. The most promising molecules from this list were synthesized and characterized in vitro and in vivo. Data on the potency, selectivity, CNS penetrance and metabolic stability of select inhibitors will be presented. In summary, the Enki™ platform has enabled accelerated drug discovery timelines and deep exploration into expanded chemical spaces, allowing identification of ATR inhibitor candidates with BBB penetrance into the CNS. Citation Format: Sarah Truong, Beibei Zhai, Louise Ramos, Mona Marzban, Fariba Ghaidi, Marshall Drew-Brook, Pete Guzzo, Ahmad Issa, Mehran Khodabandeh, Sara Omar, Jason Rolfe, Seyed Ali Saberali, Kally Singh, Xiaoqi Chen, Dennis Brown, John Langlands, Jeffrey Bacha, Mads Daugaard. Novel ATR inhibitors with CNS penetrance developed by artificial intelligence [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2025 Oct 22-26; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2025;24(10 Suppl):Abstract nr C116.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0010.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.026
GPT teacher head0.292
Teacher spread0.265 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueMolecular Cancer TherapeuticsSame topicinterferon and immune responsesFrench-language works237,207